Marker Highlights Expanded Manufacturing Support For MT-601
(RTTNews) - Marker Therapeutics, Inc. (MRKR), announced on Tuesday that its lead program MT-601 (neldaleucel) will benefit from expanded manufacturing capabilities following the formation of Kincellis Advanced Therapies, a U.S. cell therapy contract development and manufacturing